Market cap
$233 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -21.85 | -44.84 | -37.66 | -47.44 | -18.85 |
| Net Profit | -21.85 | -44.84 | -37.66 | -1.52 | -17.91 |
| EPS | -14.93 | -0.36 | 17.05 | 21.01 | 11.08 |
| Book Value | -- | -- | -32.53 | -22.20 | -24.81 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -38.97 | -38.61 | -39.14 | -31.60 | -37.88 |
| Return on Capital
| -37.21 | -36.94 | -- | -30.93 | -36.34 |
| Return on Assets
| -35.23 | -35.40 | -39.32 | -29.39 | -34.25 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
-30.93
|
-36.34
|
-44.36
|
-47.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-39.14
Higher than Peers by 1.25
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-39.14
|
-31.60
|
-37.88
|
-47.44
|
-49.96
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-39.32
Lower than Peers by 8.34
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-39.32
|
-29.39
|
-34.25
|
-42.05
|
-46.14
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
EBIT Growth
-37.66
Lower than Peers by 36.86
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-37.66
|
-28.80
|
-10.33
|
37.64
|
-42.40
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-37.66
Lower than Peers by 30.36
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-37.66
|
-28.80
|
-10.33
|
38.71
|
-39.58
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
17.05
Higher than Peers by 2.40
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
17.05
|
0.26
|
0.53
|
0.39
|
-0.39
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-22.61
Lower than Peers by 12.43
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-22.61
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
0.02
|
0.03
|
0.08
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
0.01
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
10.97
Higher than Peers by 5.16
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
10.97
|
14.58
|
15.71
|
11.17
|
15.01
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
10.97
Higher than Peers by 5.28
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
10.97
|
--
|
--
|
--
|
14.81
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-19.91
Lower than Peers by 17.82
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
-19.91
|
--
|
-10.69
|
--
|
-57.01
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
--
|
--
|
1,245.71
|
1,758.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
3,983.95
|
3,775.17
|
2,152.94
|
1,878.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
-4.27
|
-3.13
|
-0.53
|
-0.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.45
Lower than Peers by 3.73
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
1.45
|
1.25
|
0.84
|
0.31
|
0.30
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.74
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
0.74
|
-1.63
|
0.59
|
0.97
|
0.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
233
Higher than Peers by 87
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protara Therapeutics (TARA)
|
233
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|